Background and Objectives: The mainstay of therapy in patients with neuropathic stress urinary incontinence (nSUI) has been through the use of artificial urinary sphincter (AUS). AUS infection/erosion rates are higher in nSUI patients and these patients tend to be younger, increasing the likelihood of multiple AUS revisions in the future. We review our experience with mesh male slings for patients with nSUI. Methods: A retrospective review of patients who had mesh sling placement. Results: Twenty patients were identified between 2003 and 2011. 14/20 (70%) (5 = AdVance, 8 = InVance, 1 = Virtue) were available for long-term evaluation; in 6/20 (30%) the sling was removed for either infection or perineal wound breakdown. The mean time from injury to male sling was 148.2 (29-449) months. Pre-/post-op fluorourodynamic study was performed in 13 and 7 patients, respectively. There were no significant differences in ALPP (46.4 vs. 55.7 cm H2O, p = 0.106) and MCC (456.6 vs. 608 ml, p = 0.21) in the 7 patients who had a post-op study: five patients had new onset low bladder compliance and two had new onset detrusor overactivity post-sling. With a mean follow-up of 24.7 (1-66) months, 4/14 (28.6%) had no UI. Conclusions: With short-term follow-up, mesh male slings are a feasible option to treat nSUI. There appears to be a lower success rate for UI resolution, which may be attributable to new onset detrusor failure or wound infection requiring sling removal.

1.
Marks JL, Light JK: Management of urinary incontinence after prostatectomy with the artificial urinary sphincter. J Urol 1989;142:302-304.
2.
Walsh PC, Jewett HJ: Radical surgery for prostatic cancer. Cancer 1980;45(7 suppl):1906-1911.
3.
Rudy DC, Woodside JR, Crawford ED: Urodynamic evaluation of incontinence in patients undergoing modified Campbell radical retropubic prostatectomy: a prospective study. J Urol 1984;132:708-712.
4.
Holm HV, Fosså SD, Hedlund H, et al: Study of generic quality of life in patients operated on for post-prostatectomy incontinence. Int J Urol 2013;20:889-895.
5.
Gonzalez R, Koleilat N, Austin C, et al: The artificial sphincter AS800 in congenital urinary incontinence. J Urol 1989;142:512-515; discussion 520-521.
6.
Rink RC, Mitchell ME: Bladder neck/urethral reconstruction in the neuropathic bladder. Dial Ped Urol 1987;10:5.
7.
Campodonico F, Manuputty EE, Campora S, et al: Age is predictive of immediate postoperative urinary continence after radical retropubic prostatectomy. Urol Int 2014;92:276-281.
8.
Kaufman JJ: Treatment of post-prostatectomy urinary incontinence using a silicone gel prosthesis. Br J Urol 1973;45:646-653.
9.
Raz S, McGuire EJ, Ehrlich RM, et al: Fascial sling to correct male neurogenic sphincter incompetence: the McGuire/Raz approach. J Urol 1988;139:528-531.
10.
Comiter CV: The male sling for stress urinary incontinence: a prospective study. J Urol 2002;167:597-601.
11.
Ullrich NF, Comiter CV: The male sling for stress urinary incontinence: 24-month follow-up with questionnaire based assessment. J Urol 2004;172:207-209.
12.
Fassi-Fehri H, Badet L, Cherass A, et al: Efficacy of the InVance male sling in men with stress urinary incontinence. Eur Urol 2007;51:498-503.
13.
Rajpurkar AD, Onur R, Singla A: Patient satisfaction and clinical efficacy of the new perineal bone-anchored male sling. Eur Urol 2005;47:237-242; discussion 242.
14.
Rehder P, Gozzi C: Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. Eur Urol 2007;52:860-866.
15.
Dean GE, Kunkle DA: Outpatient perineal sling in adolescent boys with neurogenic incontinence. J Urol 2009;182(4 suppl):1792-1796.
16.
Groen LA, Spinoit AF, Hoebeke P, et al: The AdVance male sling as a minimally invasive treatment for intrinsic sphincter deficiency in patients with neurogenic bladder sphincter dysfunction: a pilot study. Neurourol Urodyn 2012;31:1284-1287.
17.
Schäfer W, Abrams P, Liao L, et al; International Continence Society: Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261-274.
18.
Wessells H, Peterson AC: Surgical procedures for sphincteric incontinence in the male: the artificial genitourinary sphincter and perineal sling procedures; in Kavoussi LR, Novick AC, Partin AW, Peters CA (eds): Campbell-Walsh Urology, ed 10. WB Saunders, 2011, pp 2299-2302.
19.
Petrou SP, Elliott DS, Barrett DM: Artificial urethral sphincter for incontinence. Urology 2000;56:353-359.
20.
Daneshmand S, Ginsberg DA, Bennet JK, et al: Puboprostatic sling repair for treatment of urethral incompetence in adult neurogenic incontinence. J Urol 2003;169:199-202.
21.
Bauer RM, Mayer ME, Gratzke C, et al: Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: results after 1 year. Eur Urol 2009;56:928-933.
22.
Bauer RM, Soljanik I, Füllhase C, et al: Results of the AdVance transobturator male sling after radical prostatectomy and adjuvant radiotherapy. Urology 2011;77:474-479.
23.
Soljanik I, Becker AJ, Stief CG, et al: Urodynamic parameters after retrourethral transobturator male sling and their influence on outcome. Urology 2011;78:708-712.
24.
Bauer RM, Gozzi C, Roosen A, et al: Impact of the ‘repositioning test' on postoperative outcome of retroluminar transobturator male sling implantation. Urol Int 2013;90:334-338.
25.
Bauer RM, Mayer ME, May F, et al: Complications of the AdVance transobturator male sling in the treatment of male stress urinary incontinence. Urology 2010;75:1494-1498.
26.
Cameron AP, Rodriguez GM, Schomer KG: Systematic review of urological followup after spinal cord injury. J Urol 2012;187:391-397.
27.
Danforth TL, Ginsberg DA: Neurogenic lower urinary tract dysfunction: how, when, and with which patients do we use urodynamics? Urol Clin North Am 2014;41:445-452.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.